Investor relations
A financially strong national company: revenue has nearly doubled in four years while we keep investing in capacity and quality.
Fiscal year 2019/20 at a glance
Latest published results. Figures in Egyptian pounds.
Net operating revenue · 2019/20EGP 1.02 bn+23.6% vs 2018/19
Net income · 2019/20EGP 170 m+50.7% vs 2018/19
Net equity · 2019/20EGP 572 m+18.8% vs 2018/19
Total investment · 2019/20EGP 581 m+18.3% vs 2018/19
Net operating revenue
EGP millions
Net income
EGP millions
Total investment
EGP millions
Company main indicators
In thousands of Egyptian pounds, except number of employees.
| Indicator | 2016/17 | 2017/18 | 2018/19 | 2019/20 |
|---|---|---|---|---|
| Net operating revenue | 516,940 | 708,786 | 829,096 | 1,024,816 |
| Interest expenses | 0 | 0 | 0 | 0 |
| Net income | 91,218 | 118,213 | 112,852 | 170,047 |
| Net equity | 372,492 | 434,381 | 481,267 | 571,949 |
| Working capital | 269,135 | 321,521 | 373,608 | 412,209 |
| Total investment | 378,936 | 444,400 | 490,605 | 580,557 |
| Salaries | 91,874 | 99,803 | 119,609 | 134,741 |
| Number of employees | 1,592 | 1,525 | 1,475 | 1,438 |
Annual revenue 2018USD 49.80 mat USD 1 = EGP 16.65 (30 June)
Annual revenue 2020USD 63.73 mat USD 1 = EGP 16.08 (30 June)
Investor enquiries
For corporate governance documents, disclosures and financial statements, contact the investor relations team.
- info@alexcopharma.net
- (03) 330 2228 · (03) 331 5555 · (03) 331 2223
